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Abstract 
Tuberculosis remains the leading cause of death from a single infection agent worldwide. 
In recent years, the occurrence of tuberculosis cases caused by drug-resistant strains has 
spread, and is expected to continue to grow. Therefore, the development of new 
alternative treatments to the use of antibiotics is highly important. In that sense, 
nanotechnology can play a very relevant role, due to the unique characteristics of 
nanoparticles. In fact, different types of nanoparticles have already been evaluated both as 
potential bactericides and as efficient drug delivery vehicles. In this work, the use of 
selenium nanoparticles has been evaluated to inhibit the growth of two types of 
mycobacteria: Mycobacterium smegmatis and Mycobacterium tuberculosis. The results 
showed that selenium nanoparticles are able to inhibit the growth of both types of 
mycobacteria by damaging their cell envelope integrity. These results open a new 
opportunity for the use of this type of nanoparticles as antimycobacterial agents by 
themselves, or for the development of novel nanosystems that combine the action of these 
nanoparticles with other drugs. 
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1. Introduction 
Tuberculosis (TB) is a chronic infectious disease transmitted aerially through 
droplets expelled by an infected person. The disease is caused by the slow-growing 
tubercle bacillus Mycobacterium tuberculosis (Mtb). TB is the leading cause of death due 
to infection worldwide, with approximately 1.4 million deceased in 2018 [1] and estimates 
at 75 million people dying from TB over the next 35 years. In 2018 alone, new TB cases 
were estimated to be 10.4 million worldwide [1]. Currently, TB treatment requires a six-
month regimen of four first-line drugs, which are ineffective at treating infection with 
multidrug-resistant (MDR) Mtb strains. These strains are rapidly spreading worldwide 
(more than 480,000 cases reported last year according to the TB alliance) and could cost 
$16 trillion over the next 35 years. Since microbial resistance to antibiotics increases, there 
is a call for non-antibiotic therapies that can fill the gaps for bactericidal purposes where 
antibiotics fail [2]. In the recent years, the combination of nanotechnology and biomedicine 
has proven to be promising for multiple purposes, including in bactericide applications 
[3,4,5].  
Nanoparticles are highly promising as antimicrobials, complementary to antibiotics, 
as they act by influencing the bacterial cell wall by direct contact without the need to be 
endocytosed [6,7]. Their small size implies a greater surface-area-to-volume ratio than 
bulk material. Also, they may have optical or even magnetic properties [8]. There is a great 
variety of nanoparticles in use as antimicrobials, such as metal, metal oxide or organic 
nanoparticles, involving multiple modes of action [9,10,11]. However, nanoparticles affect 
bacteria in two main lethal pathways, which can occur simultaneously: disruption of 
membrane potential and integrity, or production of reactive oxygen species (ROS) [12].  
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Selenium nanoparticles (SeNPs) have already been suggested for multiple 
biomedical applications due to their antioxidant properties and differential behavior in 
comparison to other selenospecies [13]. Also, SeNPs have been shown to have 
antimicrobial activity against different types of bacteria [14]. However, SeNPs have never 
been proven before to have an antimicrobial effect on Mtb. 
Therefore, in this work, the mycobactericidal capacity of SeNPs has been evaluated 
on two types of mycobacteria, the fast-growing Mycobacterium smegmatis (Msm) and the 
slow-growing Mtb, finding an effective inhibition in the mycobacterial growth in a dose-
dependent manner. A structural analysis of the mycobacteria subjected to the presence of 
the SeNPs has been performed by means of electron microscopy to analyze their effect on 
the cell envelope, showing that SeNPs interact directly with the mycobacteria membrane 
of Mtb and Msm, compromising their integrity and inducing extrusion of cytoplasmic 
material. 
 
2. Materials and methods 
 
2.1. Chemicals 
Reagents for the synthesis of SeNPs: chitosan, bovine serum albumin, sodium 
selenite, ascorbic and acetic acid were purchased from Sigma-Aldrich. Reagents for 
electron microscopy: glutaraldehyde, cacodylate and formaldehyde were purchased from 
Sigma. Uranyl formate was purchased from Electron Microscopy Sciences (Hatfield, PA, 
US). 
 
2.2. Synthesis of SeNPs 
Chitosan-stabilized SeNPs (Ch-SeNPs) were synthesized following the procedure 
described by Bai et al. [15]. Briefly, 10 mL of an aqueous chitosan polysaccharide solution 
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(0.5% w/v) were mixed with 7.5 mL of ascorbic acid 0.23 M and 5 mL of acetic acid 2.4 M. 
Then, 0.25 mL of sodium selenite 0.51 M were slowly added to the previous solution. 
SeNPs formation was recognized by observing the change of the solution from colorless to 
red as the reaction progressed. After the synthesis, the colloidal suspension was diluted to 
50 mL with distilled water, resulting in final concentrations of 200 mg L−1 of Se and 0.1% of 
chitosan. Finally, the colloidal suspension was dialyzed for 2 h at room temperature in a 
ratio of 10 mL against 2 L of distilled water and using a 12 kDa of MWCO membrane. 
For control experiments, BSA-SeNPs were also prepared following the same procedure 
but using an aqueous bovine serum albumin solution (0.5% w/v) instead of the chitosan 
solution. 
 
2.3. Analytical characterization of the synthesized SeNPs 
Transmission electron microscopy (TEM) was performed using a JEOL JEM 1400 
instrument operated at 120 kV equipped with a CCD camera (KeenView Camera) and an 
energy dispersive X-ray spectroscopy (EDS) analyzer. Sample preparation was performed 
by placing one or two drops of the SeNPs colloidal suspension onto carbon-coated copper 
grids.  
Electrophoretic mobility measurements of the materials suspended in water were 
used to calculate the zeta potential (ζ) values of the nanoparticles. Measurements were 
performed in a Zetasizer Nano ZS (Malvern Instruments Ltd., United Kingdom) equipped 
with a 633 nm “red” laser. The hydrodynamic size of nanoparticles was measured by 
dynamic light scattering (DLS) with the same Malvern instrument. 
 
2.4. Bacterial strains and culture conditions 
Mycobacterium smegmatis mc2155 (Msm) and Mycobacterium tuberculosis H37Rv 
(Mtb) strains (obtained from the ATCC) were grown in Middlebrook 7H9 medium 
In revi
w
6	
supplemented with 10% (v/v) OADC supplement (NaCl 8.5 g/L, BSA fraction V 50 g/L, 
dextrose 20 g/L, 5% (v/v) oleic acid solution 1%, 40 mg/L catalase), 0.5 % (v/v) glycerol 
and 0.05% Tyloxapol  (v/v; Sigma). Cultures were grown at 37 ºC in static standing 25 cm2 
flasks with vented caps. Msm-Lux was generated by transforming Msm with the plasmid 
construct pMV306hsp+Lux (which contains the entire bacterial Lux operon cloned in a 
mycobacterial integrative expression vector) [16]. 
 
2.5. Minimum inhibitory concentration (MIC) assay 
Minimum inhibitory concentration (MIC) assay was carried out in 96-well plates 
diluting exponentially growing Msm or Mtb at an initial density of 1 x 105 bacteria/mL in the 
presence of two-fold serial dilutions of Ch-SeNPs or BSA-SeNPs starting at 50 µg/mL and 
including one control sample with no NPs. Plates were incubated at 37 ºC for 7 days 
(Msm) or for 20 days (Mtb). Bacterial growth was monitored every day for Msm and every 
week for Mtb and was determined by measuring optical density at 570 nm. The assay was 
performed in triplicate. MIC values were selected as the minimum concentration able to 
suppress mycobacterial growth. Alternatively, Msm-lux was submitted to MIC assay and 
cell viability was assessed by measuring relative luminescence units (RLUs) at day 2. 
Correlation between colony forming units (CFUs) was performed according to a previously 
performed in vitro RLUs vs CFUs curve. 
 
2.6. Transmission electron microscopy (TEM) (Negative staining) 
Msm cells were fixed with 2% glutaraldehyde in 0.1 M cacodylate at room 
temperature for 2 h, and then incubated overnight in 4% formaldehyde, 1% 
glutaraldehyde, and 0.1% PBS. For negative staining of the samples, a drop of the fixed 
bacterial suspension was applied directly onto a glow-discharged EM grid (QUANTIFOIL. 
Formvar/Carbon. Cu 400 mesh grids). The sample was allowed to be adsorbed and then 
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blotted with filter paper (Whatman grade No. 1). The grid was washed by touching the 
surface with two consecutive drops of 0.75% (w/v) uranyl formate, blotting each time, and 
stained for 1 min with one more drop of the same staining agent.  Negative stained 
samples were examined in a JEOL JEM-1230 (accelerating voltage 100 kV) electron 
microscope, and images were recorded with a CCD camera ORIUS SC100 (4 × 2.7 k 
pixel). 
 
2.7. Cryo-electron microscopy (Cryo-EM) 
Msm and Mtb cultures were fixed as above prior to vitrification. Grids were prepared 
following standard procedures and observed at liquid nitrogen temperatures in a JEM-
2200FS/CR transmission electron microscope (JEOL Europe, Croissy-sur-Seine, France) 
operated at 200 kV. An in-column omega energy filter helped to record images with 
improved signal/noise ratio by zero-loss filtering. The energy selecting slit width was set at 
9 eV. Digital images were recorded on an UltraScan4000 CCD camera under low-dose 
conditions at a magnification of 55,058 obtaining a final pixel size of 2.7 Å/pixel. 
 
3. Results 
 
3.1. Synthesis and Characterization of SeNPs 
Selenium nanoparticles were prepared via a redox system in the presence of a 
biomacromolecule as soft template to control the nucleation and growth of the inorganic 
nanoselenium. The chemical reduction of selenite with ascorbic acid in the presence of a 
polysaccharide such as chitosan as stabilizer and capping agent afforded red elemental 
selenium in colloidal state [17]. Based on our previous work, 0.1 % of chitosan 
concentration was selected to prepare the SeNPs [13]. Under these conditions, the 
nanoparticles proved to be colloidally stable. Two months after their synthesis, no 
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flocculated material was present, DLS measurements showed no displacement of the 
hydrodynamic size distribution and no significant differences in the shape or size of the 
SeNPs were observed by TEM. 
Transmission electron microscopy (TEM) images show well dispersed Ch-SeNPs 
that exhibit spherical morphology and homogeneous sizes of around 60-80 nm (Fig. 1A). 
The energy dispersive spectroscopy analysis (Fig. 1B) indicates a composition in selenium 
for the Ch-SeNPs, also being observed in the spectrum the signals for C and O from 
chitosan and the carbon coated copper grid. 
The hydrodynamic size distribution of the Ch-SeNPs measured in the aqueous 
colloidal suspension (Fig. 1C) is monomodal and reasonably narrow, with a maximum 
centered at 105.7 ± 2.5 nm of diameter, which is in concordance with the smaller size of 
the inorganic nanoparticle determined in the TEM study. The ζ-potential of the Ch-SeNPs 
in water is in the zone of colloidal stability with a value of + 66.6 ± 4.7 mV. This highly 
positive value is due to the surface stabilization with chitosan, which possesses a 
equilibrium for the protonation of the amino groups in water. Therefore, chitosan allows the 
selenium nanoparticles to form stable colloidal suspensions due to both electrostatic as 
well as steric stabilization. 
 
3.2. Antimycobacterial activity of SeNPs 
We evaluated the ability of SeNPs to inhibit the growth of two different species of 
mycobacteria: the fast-growing Msm and the slow-growing Mtb. SeNPs were found to be 
effective in inhibiting mycobacterial growth in a dose-dependent manner, showing MIC 
values of 0.400 µg/mL for Msm (Supplementary Fig. S1A) and 0.195 µg/mL for Mtb (Fig. 
2A). To determine whether this inhibition was concomitant to bacterial cell death we 
generated a luciferase-expressing reporter strain of Msm (Msm-Lux) [16]. Correlation 
between relative fluorescence units (RLUs) and CFUs was previously determined 
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(Supplementary Fig. S2A) and used to calculate viable bacteria after treatment of Msm-
Lux with SeNP (Supplementary Fig. S2B). We observed a reduction in CFUs as 
concentration of NPs increased, indicating the bactericidal effect of SeNPs. By this method 
MIC was similar to that of previously determined by measuring optical density. 
To gain insight into the nature of the inhibitory effect of SeNPs, we performed 
ultrastructural analysis of Msm submitted to 0.400 µg/mL of SeNPs. Transmission electron 
micrographs of negative stained samples suggested that Msm exposed to SeNPs 
manifested reduced integrity of cell envelope leading to extrusion of cytoplasmic material, 
relative to untreated Msm (Supplementary Fig. S1B and S1C). To capture the 
antimycobacterial effect of SeNPs in a close-to-native state, treated (0.195 ug/mL) and 
untreated Msm and Mtb cells were submitted to cryo-EM. This technique revealed more in 
detail the membrane damage, both in Msm (Supplementary Fig. S1D and S1E) and Mtb 
(Fig. 2B-F). In addition, SeNPs could be spotted in direct contact with the mycobacterial 
cell wall, suggesting a direct connection between the effect of SeNPs and the reduction of 
the integrity of the mycobacterial cell envelope. 
 
4. Discussion 
 The rapid spread of antibiotic-resistant Mtb strains makes it necessary to search for 
alternative treatments. In this sense, the use of nanoparticles with mycobactericidal 
potential could be especially interesting, since nanoparticles have a high surface area, 
which means that they contain a high number of active sites to be able to interact with 
biological entities and, on the other hand, they have a high capacity to penetrate cells and 
tissues [18,19].  
Previous studies have used different types of nanoparticles, either as drug carriers 
[20] or as bactericidal agents themselves against tuberculosis. In the latter case, the 
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mycobactericidal potential of different metallic nanoparticles such as Ag [21], AgO, AgZnO 
[22] or Ga [23] nanoparticles, has been evaluated.  
Among the different nanoparticles that are being used in biomedicine, Se 
nanoparticles are especially interesting because of their low toxicity.	While Se has a 
narrow therapeutic window and the toxicity margins are very delicate, SeNPs possess 
remarkably reduced toxicity [24]and it has been proposed as a therapeutic agent for 
different applications without significant side effects [25]. As a matter of fact, it has been 
demonstrated that SeNPs are less toxic than other inorganic and organic selenospecies 
[13], showing unique properties such as their capacity for inducing cell cycle arrest [26] 
without inducing a significant degree of apoptosis [13]. In addition, SeNPs have also been 
used as a bactericidal agent against Staphylococcus aureus [27] and their anti-biofilm 
capacity has been demonstrated against S. aureus, Pseudomonas aeruginosa and 
Proteus mirabilis [28]. However, to date, the potential of Se nanoparticles against Mtb has 
not been evaluated. 
In this study, the mycobactericidal capacity of SeNPs has been demonstrated 
against two types of mycobacteria, Msm and Mtb, with MIC values of 0.400 µg/mL and 
0.195 µg/mL, respectively. Furthermore, to rule out an effect of the chitosan in the Ch-
SeNPs bactericidal action, SeNPs stabilized with a protein such as bovine serum albumin 
(BSA-SeNPs) have been evaluated on Mtb showing an inhibition on the bacterial growth at 
similar concentrations than Ch-SeNPs (Fig. 2A). Therefore, the mycobactericidal effect is 
due to the SeNPs themselves and not to the presence of the stabilizing agent chitosan. In 
agreement with the previously demonstrated bactericidal effect of SeNPs on unrelated 
bacterial pathogens, we have demonstrated that these NPs can also kill Mycobacteria. 
Furthermore, our analyses by TEM and cryo-EM have shown that SeNPs come into 
contact with the cell wall of Mtb and Msm, compromising their integrity and inducing 
extrusion of cytoplasmic material. These results open a new opportunity for the 
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development of novel nanosystems with high antimycobacterial potential that, alone or in 
combination with antibiotics, could improve the treatment of multi-drug resistant 
tuberculosis strains. 
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Figure legends 
 
Fig. 1. Characterization of the synthesized SeNPs. A) TEM images of a 200 mg L-1 
suspension of Ch-SeNPs. B) EDS spectrum of Ch-SeNPs. C) Hydrodynamic size 
distribution of the Ch-SeNPs in aqueous colloidal suspension measured by dynamic light 
scattering. 
 
Fig. 2. Antimicrobial activity of SeNPs against Mycobacterium tuberculosis. A) MIC assay 
testing the antibacterial activity of Ch-SeNPs and BSA-SeNPs after 20 days of treatment. 
(B-E) Ultrastructural analysis by cryo-EM of untreated Mtb cells (B, C) or Mtb cells treated 
with an inhibitory concentration (0.195 µg/mL) of SeNPs  (D-F).  
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